Community-Acquired Respiratory Infections in HCT and Immunosuppressed Patients

Community-acquired respiratory infections in the immunosuppressed patient population continue to be highly frequent, with negligible treatment options. The best approach is preventing infection followed by timely microbiologically based polymerase chain reaction (PCR) testing to assess which patients require droplet isolation. In terms of therapy, influenza is the only respiratory infection with an FDA-approved therapy, oseltamivir.